 | Up a level |
2020
Edelmann, Jennifer, Holzmann, Karlheinz, Tausch, Eugen, Saunderson, Emily A., Jebaraj, Billy M. C., Steinbrecher, Daniela, Dolnik, Anna, Blaette, Tamara J., Landau, Dan A., Saub, Jenny, Estenfelder, Sven, Ibach, Stefan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain 
ORCID: 0000-0002-1430-2574, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Goede, Valentin, Bullinger, Lars, Wu, Catherine J., Mertens, Daniel ORCID: 0000-0003-0227-7188, Ficz, Gabriella, Gribben, John G., Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan
(2020).
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.
Haematologica, 105 (5).
S. 1379 - 1391.
PAVIA:
FERRATA STORTI FOUNDATION.
ISSN 0390-6078
Herling, Carmen D., Cymbalista, Florence, Gross-Ophoff-Mueller, Carolin, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Busch, Raymonde, Porcher, Raphael ORCID: 0000-0002-5277-4679, Cazin, Bruno, Dreyfus, Brigitte, Ibach, Stefan, Lepretre, Stephane, Fischer, Kirsten, Kaiser, Florian, Eichhorst, Barbara, Wentner, Clemens-Martin, Hoechstetter, Manuela A., Doehner, Hartmut, Leblond, Veronique, Kneba, Michael, Letestu, Remi, Boettcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael and Levy, Vincent
(2020).
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
Leukemia, 34 (8).
S. 2038 - 2051.
LONDON:
NATURE PUBLISHING GROUP.
ISSN 1476-5551
2018
Steinbrecher, Daniela, Jebaraj, Billy Michael Chelliah, Schneider, Christof, Edelmann, Jennifer, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain ORCID: 0000-0002-1430-2574, Ibach, Stefan, Tausch, Eugen, Scheffold, Annika, Bloehdorn, Johannes, Hallek, Michael, Dreger, Peter, Doehner, Hartmut and Stilgenbauer, Stephan
(2018).
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
Leuk. Lymphoma, 59 (7).
S. 1614 - 1624.
ABINGDON:
TAYLOR & FRANCIS LTD.
ISSN 1029-2403
2014
Edelmann, Jennifer, Saub, Jenny, Ibach, Stefan, Holzmann, Karlheinz, Tausch, Eugen, Bloehdorn, Johannes, Mertens, Daniel, Zenz, Thorsten, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain, Gribben, John G., Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2014). High Resolution Genomic Profiling of Primary Ultra High Risk and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Stilgenbauer, Stephan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain, Ibach, Stefan, Choquet, Sylvain, Dartigeas, Caroline, Cazin, Bruno, Tournilhac, Olivier, Pegourie, Brigitte, Seiler, Till M., Soekler, Martin, Zirlik, Katja, Alt, Juergen, Huber, Henriette, Bloehdorn, Johannes, Tausch, Eugen, Zenz, Thorsten, Hallek, Michael, Schetelig, Johannes, Dreger, Peter and Doehner, Hartmut (2014). Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in ultra High-risk CLL: Final Results from the CLL2O Phase II Study. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Teleanu, Veronica, Edelmann, Jennifer, Haferlach, Claudia, Ibach, Stefan, Tausch, Eugen, Bloehdorn, Johannes, Leblond, Veronique, Cymbalista, Florence, Delmer, Alain, Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan (2014). Genomic Mechanisms of 17p / TP53 Loss in Primary ultra High-risk and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2012
Stilgenbauer, Stephan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain, Mack, Silja, Buehler, Andreas, Winkler, Dirk, Zenz, Thorsten, Busch, Raymonde, Ibach, Stefan, Choquet, Sylvain, Caroline, Dartigeas, Cazin, Bruno, Tournilhac, Olivier, Seiler, Till M., Zirlik, Katja, Alt, Juergen, Soekler, Martin, Schetelig, Johannes, Dreger, Peter, Hallek, Michael and Doehner, Hartmut (2012). Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971